ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Consensus PT from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $77.71.

A number of equities analysts have recently weighed in on ANIP shares. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th.

ANI Pharmaceuticals Trading Down 2.9 %

ANIP opened at $57.94 on Friday. The stock has a market capitalization of $1.22 billion, a PE ratio of -105.35 and a beta of 0.74. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business’s 50 day moving average price is $57.08 and its 200 day moving average price is $58.23.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This trade represents a 8.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,781 shares of company stock worth $2,465,372. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC increased its stake in shares of ANI Pharmaceuticals by 20.8% during the third quarter. Exchange Traded Concepts LLC now owns 12,056 shares of the specialty pharmaceutical company’s stock worth $719,000 after buying an additional 2,072 shares during the period. Assenagon Asset Management S.A. grew its holdings in ANI Pharmaceuticals by 149.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after acquiring an additional 111,613 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of ANI Pharmaceuticals by 3.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 300 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after purchasing an additional 464 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of ANI Pharmaceuticals by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 1,582 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.